Objectives: To determine the feasibility of delivering inhaled treprostinil during mechanical ventilation and spontaneous unassisted ventilation using the Tyvaso Inhalation System and the vibrating mesh nebulizer. We sought to compare differences in fine particle fraction, and absolute inhaled treprostinil mass delivered to neonatal, pediatric, and adult models affixed with a face mask, conventional, and high-frequency ventilation between Tyvaso Inhalation System and with different nebulizer locations between Tyvaso Inhalation System and vibrating mesh nebulizer. Design: Fine particle fraction was first determined via impaction with both the Tyvaso Inhalation System and vibrating mesh nebulizer. Next, a test lung configured with neonatal, pediatric, and adult mechanics and a filter to capture medication was attached to a realistic face model during spontaneous breathing or an endotracheal tube during conventional ventilation and high-frequency oscillator ventilator. Inhaled treprostinil was then nebulized with both the Tyvaso Inhalation System and vibrating mesh nebulizer, and the filter was analyzed via high-performance liquid chromatography. Testing was done in triplicate. Independent two-sample t tests were used to compare mean fine particle fraction and inhaled mass between devices. Analysis of variance with Tukey post hoc tests were used to compare within device differences. Setting: Academic children's hospital aerosol research laboratory. Measurements and Main Results: Fine particle fraction was not different between the Tyvaso Inhalation System and vibrating mesh nebulizer (0.78 ± 0.04 vs 0.77 ± 0.08, respectively; p = 0.79). The vibrating mesh nebulizer delivered the same or greater inhaled treprostinil than the Tyvaso Inhalation System in every simulated model and condition. When using the vibrating mesh nebulizer, delivery was highest when using high-frequency oscillator ventilator in the neonatal and pediatric models, and with the nebulizer in the distal position in the adult model. Conclusions: The vibrating mesh nebulizer is a suitable alternative to the Tyvaso Inhalation System for inhaled treprostinil delivery.
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Inhaled nitric oxide has been shown to improve oxygenation and decrease the need for extracorporeal membrane oxygenation in infants with hypoxic respiratory failure (4), but it is costly and requires specialized equipment. Inhaled epoprostenol is a less costly alternative and has been shown to improve the oxygenation index while maintaining systemic arterial pressure in neonates with persistent pulmonary hypertension of the newborn that are refractory to inhaled nitric oxide therapy (5). However, epoprostenol is not approved for inhaled use and is an alkaline sticky solution which can clog nebulizers (6) , and even a brief discontinuation in nebulization could result in rebound pulmonary hypertension. This drug is also unstable at room temperature and has a short serum half life (< 6 min) (7) . Inhaled iloprost has a longer serum half life (20-30 min) than epoprostenol (< 6 min) which allows it to be delivered with intermittent nebulization (8) and has been shown to be as effective as inhaled nitric oxide at improving ventilation and perfusion matching (9) . Inhaled treprostinil has been shown to be effective and safe in both adults (10, 11) and children (12) and has reportedly fewer systemic side effects than inhaled iloprost. Treprostinil has a half life up to 4 hours (8), which allows therapy to be given less frequently than iloprost. Currently, the only Food and Drug Administration approved nebulizer for delivery is via the Tyvaso (treprostinil) Inhalation System (TIS) (United Therapeutics, Silver Springs, MD) which incorporates an ultrasonic nebulizer (OPTINEB-ir; NEBU-TEC, Elsenfeld, Germany) as the aerosol generator. This system provides automatic timed actuations of the nebulized medication and is meant for awake and cooperative patients as the patient must inhale when alerted to do so by the device. As such, the TIS is not intended to be used during mechanical ventilation and there are currently no recommendations for selecting aerosol delivery devices or how those devices should be configured within the patient circuit to efficiently deliver inhaled treprostinil during mechanical ventilation. Delivery with a jet nebulizer has been reported (13) , but this adds gas flow into the system which may affect ventilator function as well as the patient's ability to trigger the ventilator (14) . Many institutions are using vibrating mesh nebulizers (VMNs) to deliver inhaled medications during mechanical ventilation because it does not affect ventilator parameters or function (14) ; however, there are no published in vitro or in vivo studies describing the efficacy of inhaled treprostinil delivery with a VMN in mechanically ventilated or spontaneous breathing patients.
We sought to explore the possibility of using a VMN (AeronebSolo, Aerogen, Galway, Ireland) to deliver inhaled treprostinil in a variety of simulated conditions and in vitro patient models including an infant, pediatric, and adult model. The objectives of this study were to determine whether there were differences in treprostinil drug delivery between VMN and TIS with respect to 1) respirable particle size or fine particle fraction (FPF); 2) lung model filter mass during spontaneous breathing and two different forms of invasive mechanical ventilation; and 3) lung model filter mass at different nebulizer circuit positions/locations during mechanical ventilation.
MATERIALS AND METHODS

FPF
The total mass of inhaled treprostinil delivered within the respirable particle range of the human respiratory tract was quantified with the VMN and TIS using a multistaged Next Generation Impactor (NGI; Copley Scientific, Nottingham, United Kingdom) (for technical details, see Supplemental Digital Content 1, http://links.lww.com/PCC/A447). Each type of nebulizer was tested in triplicate with a new nebulizer used each time. To ensure detectable amounts of drug at the various stages of the NGI, larger than clinically recommended doses were used. Inhaled treprostinil was placed in the VMN (0.84 mL, 504 µg) and it was nebulized through the NGI throat with an occlusive rubber fitting adapter until dry; no residual medication was noted. Inhaled treprostinil was then placed in the TIS and 84 inhalations (6 µg per inhalation, 504 µg total) were actuated. Any residual medication left in the cup of the TIS was collected and measured to determine total dose delivered. Drug was eluted from the NGI throat and collection cups using ethanol (20 mL for the throat and 10 mL for the trays) and placed into labeled collection cups. The collection cups were immediately washed and dried following sample recovery.
Lung Model
An ASL 5000 test lung (Ingmar Medical with software package, version 3.2; Pittsburgh, PA) was configured for term neonate, small child, and adult models used with spontaneously breathing and ventilator assisted breathing, as shown in Table 1 .
Two bacterial/viral electret filters (Respirgard-II, Vital Signs; Englewood, CO) were connected in series between the distal tip of the endotracheal tube (or at the end of the realistic upper airway model during mask delivery) and the lung model. One filter Pediatric Critical Care Medicine www.pccmjournal.org e255 was used to collect the drug delivered, whereas the second filter was used to protect the internal components of the lung model.
Ventilator and Humidification
Two ventilators, a SERVO-i (Maquet, Solna, Sweden) conventional critical care ventilator and a Sensor Medics 3100 A or 3100 B high-frequency oscillator ventilator (HFOV) (Carefusion, Yorba Linda, CA), equipped with respective heated wire circuits were used for this study. A Fisher & Paykel MR730 heater (Fisher & Paykel, Auckland, New Zealand) was used for humidification with all ventilators and the temperature was allowed to stabilize for 30 minutes prior to testing. The choice of setup and settings was based on what is commonly used in the clinical setting at our institutions. A ventilator preuse check was performed per manufacturer recommendations prior to testing. Table 1 shows the ventilator settings used during conventional and HFOV ventilation.
Nebulizers
An AeronebSolo VMN (Aerogen, Galway, Ireland) was used for testing. The VMNs were placed in-line using the specialized Aerogen adaptors provided for use with mechanical ventilation. A Pro-X controller unit (Aerogen, Galway, Ireland) in continuous mode was used to power the nebulizers (for further device description, see Supplemental Digital Content 2, http://links. lww.com/PCC/A447). A TIS was also used for testing. The TIS is a OPTINEB-ir (NEBU-TEC med; Elsenfeld, Germany) Microprocessor controlled ultrasonic nebulizer configured for delivery of inhaled treprostinil during timed inhalation periods. Since the TIS is not designed for use with mechanical ventilation, it required use of several adapters to be placed in the circuit.
Nebulizer Position During Mechanical Ventilation
Two nebulizer conditions (Fig. 1A) were tested during conventional ventilation, proximal (nebulizer placed between the patient wye connector and the inspiratory limb), and distal, (nebulizer placed on the inlet of the humidifier). During HFOV, nebulizer placement in the distal position has been shown to deliver negligible medication (15) , thus only delivery in the proximal position was tested (nebulizer placed between patient wye connector and ETT) (Fig. 1B) .
Medication Delivery During Mechanical Ventilation
The nebulizers were placed in their respective positions for the condition being tested, and the system heat and humidification were allowed to stabilize 20 minutes prior to testing at each condition. When testing was performed with the TIS, one ampule of inhaled treprostinil (2.9 mL, 1.74 mg) was placed in the medication cup and nine inhalations at 6 µg per inhalation (54 µg total) were delivered in each condition. In the conventional mechanical ventilation conditions, the manual breath key on the SERVO-i was used to coordinate ventilator breaths with TIS inhalations. During HFOV, there was no attempted coordination of nebulizer actualization with inhalations due to the rapid respiratory rate. The medication cup was discarded, nebulizer components were replaced, and adapters were rinsed with sterile water and allowed to dry completely between each testing condition. The TIS nebulizes only periodically in time intervals that may, with difficulty, be synchronized with a ventilator, whereas the VMN will nebulize continuously, thus drug delivery during exhalation is considered to be negligible (14) . To accommodate for this increase in waste with the VMN, the 54 µg dosage was adjusted to account for total cycle time spent in inspiration versus expiration using the equation, 54 µg × (I + E)/600 µg/mL, assuming an I:E ratio of 1:3, then 0.36 mL (216 µg) was used with the VMN.
The adjusted inhaled treprostinil dose was drawn up into a 1 mL filter needle syringe, placed into the VMN, and nebulized until dry. Special care was taken to position the filter superior to the endotracheal tube to avoid fluid condensate from accumulating in the tube and falling into the filter when a heated humidifier was used (mechanical ventilation). Testing was completed when all of the solution was nebulized. The bacterial/viral electret filter at the end of the endotracheal tube was removed, labeled, and recorded in a laboratory notebook and placed into a refrigerator. Between each testing condition, the VMN and endotracheal tubes were rinsed with sterile water and allowed to dry completely to reduce the delivery of residual medication delivery with subsequent testing or the likelihood of large drug molecules reaching the filter.
Medication Delivery via Face Mask
The VMN and TIS were attached to a realistic anatomic face/upper airway and spontaneously breathing lung model configured for a newborn, small child, and adult using a tight fitting mask (Fig. 2) . The realistic airway models used in the current study have been described elsewhere (16) . A Vital Signs Adult size five mask (BD, Franklin Lakes, NJ) was placed on an adult airway model; Vital Signs Toddler size three mask was placed on a child (5 yr) model; and Vital Signs neo size one mask was placed on an infant nasal model. We selected nonvented masks because it is suggested that eye and skin contact of inhaled Treprostinil should be avoided in patients. The same dosing and drug delivery strategy for the VMN and TIS nebulizer delivery was used during the mask spontaneous breathing condition as those used in the ventilation conditions.
Inhaled Treprostinil Measurement
Inhaled treprostinil was recovered from the bacterial/viral electret filter following nebulization and quantified using 
Data Analysis
Inhaled treprostinil concentrations were recorded in an Excel (Microsoft, Redmond, WA) spread sheet and expressed as the absolute mass (µg) that adhered to and was recovered from the respective filters or collection cups (NGI) and was recovered from the filter or collection cup of the impactor. FPF was calculated as the ratio of inhaled fine particle mass to the total mass of drug inhaled as aerosol (17) . In this experiment, particles were considered fine if they adhered to collection cups on stages 3-7 of a NGI, corresponding with a respirable particle size range of 0.98-5.39 µg median diameter (D50).
All data were expressed as mean ± sd (n = 3 tests for each model, condition, and device). Statistical analyses were performed using R Statistical Software (version 3.1.2; R Foundation for Statistical Computing, Vienna, Austria). An independent T test was done to compare the mean FPF of inhaled treprostinil between the TIS and VMN. Independent T tests were also performed to compare differences between mean inhaled treprostinil mass (µg) from the two nebulizers, stratified by condition and lung model. Within nebulizer types, the differences in inhaled treprostinil mass (µg) in-between nebulizer conditions were explored via one-way analysis of variance with post hoc Tukey tests. Statistical significance was set a priori at p value of less than 0.05.
RESULTS
FPF
The fraction of aerosol particles mass that are considered fine (deposited in stage 3-7 of the NGI) between the two nebulizers is shown in Figure 3 . The total FPF of inhaled treprostinil was not different between the VMN and TIS (0.78 ± 0.04 vs 0.77 ± 0.08, respectively; p = 0.79).
Delivery Between Devices
The inhaled treprostinil mass (µg) for each condition is shown in Figure 4 . The VMN delivered greater inhaled treprostinil than the TIS in every simulated model and nebulizer condition (p < 0.05), except when no statically significant differences occurred between the TIS and VMN when using the pediatric model with the nebulizers in the distal position (34.6 ± 0.6 and 25.5 ± 4.4 µg, respectively; p = 0.07), face mask condition (16.1 ± 2.5 and 14.2 ± 0.4 µg, respectively; p = 0.33), and when using the adult model with the nebulizers in the proximal position (30.1 ± 3.2 and 33.3 ± 4.6, respectively; p = 0.39).
Delivery Between Nebulizer Conditions (TIS)
In the neonatal model, delivery was highest during HFOV (11.6 ± 0.8 µg; p < 0.01), whereas in the pediatric and adult model, delivery was highest with the nebulizer in the distal positions (36.6 ± 0.6 and 50.1 ± 4.5 µg, respectively; p < 0.01). The TIS in the proximal position delivered more drug than the distal and mask position only in the neonatal model (7.1 ± 1.8 vs 3.1 ± 0.6 and 1.2 ± 0.1 µg, respectively; p < 0.01). In the adult model, placing the nebulizer in the proximal or HFOV position delivered more drug than in the mask position (30.1 ± 3.2 and 22.7 ± 4.1 µg, respectively, vs 6.7 ± 0.8 µg; p < 0.01).
Delivery Between Nebulizer Conditions (VMN)
In the neonatal and pediatric models, delivery was greatest during HFOV (68.2 ± 6.3 and 63.1 ± 2.3 µg, respectively; p < 0.01). In the adult model, delivery was greatest with either HFOV or the distal position (47.5 ± 5.5 and 61.5 ± 2.3 µg, respectively; p < 0.01). Delivery was higher in the distal position than the mask position in the pediatric model (25.3 ± 4.4 vs 14.2 ± 0.4 µg; p < 0.01). In the adult model, delivery was higher with the nebulizer in the proximal position than the mask position (33.3 ± 4.6 vs 19.5 ± 0.6 µg; p < 0.01).
DISCUSSION
The efficacy of inhaled drugs is highly dependent on the deposition of medication throughout the lungs (18) . Our data suggest that when inhaled treprostinil is nebulized with either the VMN or the TIS, the FPF is similar between devices and that the majority of the particles are sufficiently small to be adequately deposited in the lung. Our reported FPF of 0.78 with the TIS and 0.77 with the VMN should be sufficiently high enough to provide adequate lung deposition as previous work has been done to demonstrate a reasonable correlation between in vitro FPF (< 5.8 µg) and in vivo whole lung deposition (19) . Other investigators have reported inhaled treprostinil FPF with some differing results. Patel et al (13) reported a higher inhaled treprostinil FPF of 0.98 when using the Aerotech II small volume nebulizer placed in-line with a ventilator, whereas Sidler-Moix et al (20) reported a lower FPF of 0.47-0.54 when nebulizing albuterol with a VMN. Differences in reported FPFs may be expected however as it has been shown that device differences or the physiochemical properties of a substance may affect FPF (21) . We are the first to report FPF of inhaled treprostinil when using a VMN and these results should be confirmed, and ideally with in vivo/in vitro correlations using the VMN with the target adult maintenance dosage of 54 µg.
We quantified the amount of inhaled treprostinil delivered when using the VMN versus the TIS in a variety of conditions and models. Overall the VMN delivered as much if not more inhaled treprostinil mass as the TIS in every condition and patient model. We used an adjusted dose based on total cycle time (54 µg × [I + E]/600 µg/mL) for the VMN to account for drug loss when nebulizing continuously during the expiratory phase to achieve a target filter dose of 54 µg which is the target maintenance dose per the label claim. Patel et al (13) used a similar approach when nebulizing inhaled treprostinil, although the algorithm differed slightly and was calculated as number of breaths needed = 29 seconds/inspiratory time, so for inspiratory times shorter than 1 second, the number of breaths needed would be higher than 29. However, the lowest inspiratory time they reported was 0.7 seconds, whereas our lowest inspiratory time was 0.4 seconds during conventional ventilation. In general, their adjusted dosing and our adjusted dosing were intentionally higher to offset losses that occurred during exhalation. When using their dosing algorithm, Patel et al (13) also delivered higher than target dosages in some of their ventilator conditions which were similar to our findings. There are some concerns in regard to the potential for overdosing with inhaled treprostinil with an adjusted dose with a VMN. The label claims a target single treatment maintenance dose of inhaled treprostinil is 54 µg four times a day in adults; however, the recommendation is to start with a lower dose of 18 µg and titrating up slowly as tolerated over several weeks to the maintenance dose to avoid systemic adverse effects. Nelsen et al (22) reported in healthy adults that when delivering a 90 µg as a single dose to healthy adults, there were adverse events of chest pain, chest discomfort, nausea, and vomiting. It is for this reason that the maximum tolerable dose was determined to be 84 µg. The highest dosages we achieved were during HFOV and they were all below the maximal tolerable dose found by Nelsen et al (22) ; however, the maximal tolerable dose of 84 µg for adults may be lower in children, and our reported doses of 74 and 65 µg that occurred during HFOV for our neonatal and pediatric models, respectively, may exceed or approach the limit for a tolerable dose, thus we recommend to approach dosing cautiously when using HFOV for neonates and pediatrics. Takatsuki et al (12) are the only investigators to report a few adverse events of mild or moderate hypotension in children with inhaled treprostinil use, and these cases resolved without any interventions. However, further work should be done to describe these adverse events in infants and children particularly when given during high-frequency ventilation when there is a greater chance for overdosing.
We characterize differences in inhaled treprostinil delivery with both the VMN and TIS when placing the nebulizer in different conditions (face mask, proximal and distal positions during mechanical ventilations, and HFOV). Our in vitro results demonstrate that nebulizer condition plays a key role in inhaled treprostinil delivery across different patient models for the VMN and TIS. Nebulizer position during conventional ventilation impacts aerosol delivery greatly and seems to be related to circuit size, bias flow, and tidal volume, where the optimal nebulizer position may vary across different patient and model sizes and conditions (23) (24) (25) (26) (27) . Our results are similar to Ari et al (23) in that we did not find a significant difference between the proximal and distal positions of the VMN with the pediatric model, but we did find larger delivery with the nebulizer in the distal position with the adult model. Our data also confirm similar findings with DiBlasi Figure 3 . Fraction of respirable fine particle mass in lung impactor. It shows the fraction of particle mass (%) between nebulizer types across the different stages of the next generation aerosol impactor. The shaded gray area (stages 3-7; mass median aerodynamic diameter) represents the fraction of fine particle mass delivered to the collection cups of the impactor. TIS = Tyvaso Inhalation System, VMN = vibrating mesh nebulizer.
Pediatric Critical Care Medicine www.pccmjournal.org e259 et al (27) who observed greater nebulized iloprost delivery in the proximal than distal position for their neonatal model. Generally, as model size increases, drug delivery tends to increase as well in in vitro studies due to the advantages of increased tidal volumes and larger bore circuitry (15, 23) . We speculate that the larger observed differences in drug delivery in the distal position with adult testing may be best explained by the reservoir-like effect of the aerosol gathering in the inspiratory limb during exhalation which may result in a larger bolus of drug delivered to the lungs than when the nebulizer is placed proximally. This relationship is different with infant conventional ventilator testing due to high respiratory rates, short inspiratory times, and small tidal volumes. These effects are described in greater detail elsewhere (23) (24) (25) (26) (27) (28) . Our results also demonstrate superior aerosol delivery when using a VMN during HFOV in our infant and pediatric models compared with conventional ventilation which confirms reports by DiBlasi et al (27) and Alzahrani (28) .
As with other in vitro studies, the results of this study must be approached cautiously. The amount of drug delivered to the filter represents the total mass of available drug delivered distal to the artificial airway, but it does not take into account the amount of aerosol that would normally be exhaled. The total cycle time adjusted dose for the VMN is under the assumption that the TIS actuations would all be synchronized during inspiration, but the TIS inspiration time is static at 2.5 seconds so any inspiratory time shorter than 2.5 seconds will result in some waste where the TIS is nebulizing during the expiratory phase of a ventilator breath. In these instances where inspiratory time is shorter, the VMN would be given an advantage over the TIS when increasing the dose of the VMN alone as we did in this study. Additional limitations include using only one particular brand of critical care conventional and high-frequency ventilator, humidifier, circuit, lung model setting, and ventilator settings.
CONCLUSIONS
Given these findings, it would seem that the VMN is a suitable alternative to the TIS for inhaled treprostinil delivery with both mechanical ventilation and spontaneous breathing. The VMN provides a sufficiently high FPF suitable for lung deposition, and when using an adjusted inhaled treprostinil dose calculated based upon the total cycle time using the equation: dose × (I + E)/600 µg/mL. VMN delivery meets or exceeds delivery of the TIS. For optimal inhaled treprostinil delivery during conventional ventilation, we recommend placing the VMN proximal to the patient wye in an infant circuit and distal to the humidifier in a pediatric circuit. Placing the VMN distal to the humidifier during conventional ventilation or proximal to the endotracheal tube during HFOV may result in higher than expected doses. In these cases, patients should be monitored closely for adverse effects. We used the target maintenance dose of 54 µg per treatment session in this in vitro study; however, for clinical use, the healthcare professionals should refer to the full prescribing information. The symbol " §" indicates dose was higher at this position than all other positions p < 0.05, "ǁ" indicates dose was higher at this position that the distal and mask positions p < 0.05, " †" indicates dose was higher at this position than the mask position p < 0.05, and " ‡" indicates dose was higher at this position than the proximal and mask positions p < 0.05. HFOV = high-frequency oscillatory ventilation, TIS = Tyvaso Inhalation System, VMN = vibrating mesh nebulizer.
